Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease

Research output: Contribution to journalJournal articleResearchpeer-review

  • Juan C Ravell
  • Mami Matsuda-Lennikov
  • Samuel D Chauvin
  • Juan Zou
  • Matthew Biancalana
  • Sally J Deeb
  • Susan Price
  • Helen C Su
  • Giulia Notarangelo
  • Ping Jiang
  • Aaron Morawski
  • Chrysi Kanellopoulou
  • Kyle W Binder
  • Ratnadeep Mukherjee
  • James T Anibal
  • Brian Sellers
  • Lixin Zheng
  • Tingyan He
  • Alex B George
  • Stefania Pittaluga
  • Astin Powers
  • David E Kleiner
  • Devika Kapuria
  • Marc Ghany
  • Sally Hunsberger
  • Jeffrey I Cohen
  • Gulbu Uzel
  • Jenna Bergerson
  • Lynne Wolfe
  • Camilo Toro
  • William Gahl
  • Les R Folio
  • Helen Matthews
  • Pam Angelus
  • Ivan K Chinn
  • Jordan S Orange
  • Claudia M Trujillo-Vargas
  • Jose Luis Franco
  • Julio Orrego-Arango
  • Sebastian Gutiérrez-Hincapié
  • Niraj Chandrakant Patel
  • Kimiyo Raymond
  • Turkan Patiroglu
  • Ekrem Unal
  • Musa Karakukcu
  • Alexandre Gr Day
  • Pankaj Mehta
  • Evan Masutani
  • Suk S De Ravin
  • Harry L Malech
  • Grégoire Altan-Bonnet
  • V Koneti Rao
  • Michael J Lenardo

X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia (XMEN) disease is caused by deficiency of the magnesium transporter 1 gene (MAGT1). We studied 23 XMEN patients, 8 of whom were EBV-naïve. We observed lymphadenopathy (LAD), cytopenias, liver disease, cavum septum pellucidum, and increased CD4-CD8-B220-TCRalpha/beta+ T (abDNT) cells, in addition to the previously described features of an inverted CD4:CD8 ratio, CD4+ T lymphocytopenia, increased B cells, dysgammaglobulinemia, and decreased expression of the "Natural-Killer Group 2, member D" (NKG2D) receptor. EBV-associated B cell malignancies occurred frequently in EBV-infected patients. We investigated XMEN patients and autoimmune lymphoproliferative syndrome (ALPS) patients by deep immunophenotyping (32 immune markers) using Time of Flight Mass Cytometry (CyTOF). Our analysis revealed that the abundance of two populations of naïve B cells (CD20+CD27-CD22+IgM+HLA-DR+CXCR5+CXCR4++CD10+CD38+ and CD20+CD27-CD22+IgM+HLA-DR+CXCR5+CXCR4+CD10-CD38-) could differentially classify XMEN, ALPS, and normal individuals. We also performed glycoproteomics analysis on T lymphocytes and show that XMEN disease is a congenital disorder of glycosylation that affects a restricted subset of glycoproteins. Transfection of MAGT1 mRNA enabled us to rescue proteins with defective glycosylation. Together, these data provide new clinical and pathophysiological foundations with important ramifications for the diagnosis and treatment of XMEN disease.

Original languageEnglish
JournalThe Journal of Clinical Investigation
Publication statusE-pub ahead of print - 5 Nov 2019
Externally publishedYes

ID: 230896116